These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 2163227)
1. [How to standardize low molecular weight heparins]. Doutremepuich C; Puyal C; Lalanne MC; Doutremepuich F; De Sèze O Ann Biol Clin (Paris); 1990; 48(4):221-5. PubMed ID: 2163227 [TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization. Barrowcliffe TW; Thomas DP Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin). Persson E Acta Med Scand Suppl; 1988; 724():1-56. PubMed ID: 2843005 [TBL] [Abstract][Full Text] [Related]
4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities. Peyrou V; Béguin S; Boneu B; Hemker HC Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588 [TBL] [Abstract][Full Text] [Related]
5. Measurement of low molecular weight heparin ex vivo activities in clinical laboratories using various anti-Xa assays: interlaboratory variability and requirement for an agreed low molecular weight heparin standard. Sié P; Aillaud MF; de Prost D; Droullé C; Forestier F; Guedj P; Juhan-Vague I; Polack B; Potron G; Roncato M Thromb Haemost; 1987 Oct; 58(3):879-83. PubMed ID: 2829376 [TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348 [TBL] [Abstract][Full Text] [Related]
8. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins. Dignac M; Gabaig AM; Cambus JP; Boneu B Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901 [TBL] [Abstract][Full Text] [Related]
9. [From heparin to heparins: toward new therapeutic perspectives?]. Molho P; Tobelem G Biomed Pharmacother; 1987; 41(4):171-5. PubMed ID: 3620582 [TBL] [Abstract][Full Text] [Related]
10. Mechanism of low-molecular-weight heparin reversal by platelet factor 4. Fiore MM; Mackie IM Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Eriksson BI; Söderberg K; Widlund L; Wandeli B; Tengborn L; Risberg B Thromb Haemost; 1995 Mar; 73(3):398-401. PubMed ID: 7667822 [TBL] [Abstract][Full Text] [Related]
13. Production and chemical processing of low molecular weight heparins. Linhardt RJ; Gunay NS Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711 [TBL] [Abstract][Full Text] [Related]
14. Are the available low-molecular-weight heparin preparations the same? Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734 [TBL] [Abstract][Full Text] [Related]
15. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers. Pindur G; Heiden M; Köhler M Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345 [TBL] [Abstract][Full Text] [Related]